School of Biological Sciences and Technology, Chonnam National University, Gwangju 500‑757, Republic of Korea.
Int J Mol Med. 2013 Jan;31(1):179-87. doi: 10.3892/ijmm.2012.1183. Epub 2012 Nov 15.
Enalapril and nifedipine are used as antihypertensive drugs; however, the therapeutic target molecules regulated by enalapril and nifedipine have yet to be fully identified. The aim of this study was to identify novel target genes that are specifically regulated by enalapril and nifedipine in tissues from spontaneously hypertensive rats (SHR) using DNA microarray analysis. We found that administration of SHR with enalapril and nifedipine differentially regulated 33 genes involved in the pathogenesis of cardiovascular diseases. Furthermore, we identified 16 genes that have not previously been implicated in cardiovascular diseases, including interleukin-24 (IL-24). Among them, exogenous administration of IL-24 attenuated the expression of vascular inflammation and hypertension-related genes induced by H2O2 treatment in mouse vascular smooth muscle (MOVAS) cells. This study provides valuable information for the development of novel antihypertensive drugs. In addition, the genes identified may be of use as biomarkers and therapeutic targets for cardiovascular diseases, including hypertension.
依那普利和硝苯地平被用作抗高血压药物;然而,依那普利和硝苯地平调节的治疗靶标分子尚未完全确定。本研究的目的是使用 DNA 微阵列分析鉴定新型的靶基因,这些靶基因是由依那普利和硝苯地平在自发性高血压大鼠(SHR)组织中特异性调节的。我们发现,给予 SHR 依那普利和硝苯地平可差异调节 33 个与心血管疾病发病机制相关的基因。此外,我们还鉴定了 16 个以前与心血管疾病无关的基因,包括白细胞介素-24(IL-24)。其中,外源性给予 IL-24 可减弱 H2O2 处理诱导的小鼠血管平滑肌(MOVAS)细胞中血管炎症和高血压相关基因的表达。本研究为开发新型抗高血压药物提供了有价值的信息。此外,所鉴定的基因可能可作为心血管疾病(包括高血压)的生物标志物和治疗靶标。